iN-KEY: Developing an off-the-shelf immunotherapy for multiple myeloma

The Horizon Europe funded project iN-KEY (iNK Cell – Driven Strategies for Enhanced Multiple Myeloma ImmunotherapY) aims to develop an innovative, ready-made myeloma treatment using immune cells called natural killer (NK) cells.

Unlike current personalised CAR T-cell therapies, which are manufactured using each patient’s own cells, iN-KEY will develop a therapy made from cells grown in advance. The aim is to create a treatment that could be prepared ahead of time and made available when needed, potentially reducing manufacturing delays and costs.

MPE is a full partner in the project, helping ensure that patients’ perspectives and needs are considered throughout the research and development of the planned clinical trial.

Why is a new approach needed?

CAR T-cell therapies are immunotherapies that are used to treat myeloma and other cancers. In myeloma, two CAR T-cell products have been approved in the European Union. These treatments use a patient’s own T-cells (immune cells that can recognise and kill cancer cells) which are genetically modified to target a protein called B-cell maturation antigen (BCMA), found on the surface of myeloma cells. Although these therapies have demonstrated survival benefits, they also present significant challenges.

Personalised CAR T-cell therapies are complex to manufacture. Patients must undergo T-cell collection, individualised manufacturing and quality checks before receiving their treatment. They also need a course of chemotherapy beforehand to prepare their body for the modified cells. The process can take several weeks, during which additional treatment may be needed to control the disease. Manufacturing delays or failures can also affect whether and when a patient receives treatment. In addition, previous treatments can leave patients’ T-cells weakened or less able to function effectively, potentially affecting the performance of the final therapy.

What is iN-KEY’s innovative approach?

Instead of starting from each patient’s own cells, the therapeutic cells will be manufactured from induced pluripotent stem cells (iPSCs). iPSCs are cells that have been genetically reprogrammed so they can develop into many different cell types, including immune cells. They can be grown and multiplied in the laboratory, creating a renewable source of cells for manufacturing therapies. This approach could allow therapeutic cells to be produced in batches for use in multiple patients, rather than relying on the collection and manufacture of each patient’s own immune cells.

The therapy developed in the iN-KEY project will use natural killer (NK) cells, a type of immune cell that naturally kills cancer cells and cells infected by viruses. Unlike some other donor-derived immune cells, NK cells generally carry a lower risk of causing graft-versus-host disease, a complication in which transplanted immune cells attack the recipient’s healthy tissues.

The NK cells developed in the iN-KEY project will be derived from iPSCs and genetically modified in three ways to help the immune system target myeloma cells more effectively while improving patient safety:

  1. The NK cells will be equipped with a chimeric antigen receptor (CAR) and hence turn them into CAR-NK cells to help them recognise the protein BCMA on myeloma cells and target them for destruction.
  2. The engineered NK cells will also be designed to produce and release bispecific antibodies. These antibodies can bind to two different targets, bringing immune cells and myeloma cells into close contact so that the immune system can attack the cancer.
  3. The engineered NK cells are designed to add an additional layer of safety not currently available with authorised CAR-T products, allowing the cell product to be rapidly eliminated in the event of life-threatening side effects.

What will the iN-KEY project do?

Over five years, the consortium will work to develop and evaluate this therapy through several stages:

  • Develop the therapy by genetically modifying iPSCs for targeting myeloma and generating NK cells from them
  • Test it in the laboratory to study how effectively the cells recognise and kill myeloma cells in cell cultures
  • Perform preclinical tests to investigate its activity and safety in a mouse model
  • Manufacture the product and test it in a first-in-human clinical trial.

How is MPE involved?

As a full partner of iN-KEY, MPE will, throughout the project:

  • Ensure patients’ needs and perspectives are considered throughout the entire project and across all work packages, to integrate them in the study design
  • Provide feedback on patients’ experiences and unmet needs throughout the treatment journey, helping to make the trial more patient-centred, accessible and inclusive
  • Co-develop the clinical trial protocol and identify relevant quality-of-life outcomes
  • Co-develop patient information and informed consent materials
  • Collaborate with regulatory bodies
  • Develop educational materials and engage in dissemination activities

Who is funding and carrying out iN-KEY?

The iN-KEY consortium is funded by Horizon Europe with almost EUR 10 million over the next five years. The project is led by the Banc de Sang i Teixits in Spain and the international partnership includes representatives from scientific, industry, and healthcare sectors: Consejo Superior de Investigaciones Cientificas (CSIC), Spain; EATRIS ERIC (EATRIS), Netherlands; Paul-Ehrlich-Institut (PEI), Germany; Commissariat à l’énergie atomique et aux énergies alternatives (CEA), France; Catalent Düsseldorf (CAT), Germany; Avanther Therapeutics (AVANT), Spain; Miltenyi Biotec (MIL), Germany; STAb Therapeutics (STX), Spain; Institut Catala d’Oncologia (ICO), Spain; Myeloma Patients Europe AISBL, Belgium; and Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO), Spain. For more information on iN-KEY please view the launch press release here.

iN KEY logo
 

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them. Grant Agreement No 101287295.